Artivion, Inc. (AORT) Stock

Artivion, Inc. (AORT) is a Healthcare stock trading at $27.96 (as of 2026-08-20), with a market capitalization of $1.36B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues for procedures in areas including cardiac, vascular, neurologic, and pulmonary care. Its offerings include products such as BioGlue and PhotoFix, preservation and related services, stent graft systems for aortic and peripheral vascular disease, and synthetic vascular grafts used in open aortic and peripheral surgeries.

Understand Artivion, Inc.: how it makes money

Artivion makes and distributes medical devices and implantable tissues (including BioGlue and aortic stent grafts), and it earns revenue from product sales and preservation services.

Profit appears to hinge on translating high gross margin (64.9%) into a relatively thin operating margin (5.0%), so the mix and scale of product revenue and preservation services must cover operating costs.

Revenue by segment (latest quarter)
Products$0.1B
Preservation$0.0B

Business quality (Mixed): Good high-level profitability signals (gross margin and operating margin) are provided, but the available operating metrics are revenue line items only, and the segment breakdown is limited for drivers beyond product and preservation sales.

Valuation: At 80× earnings, AORT trades 149% above the Medical Equipment average (32×). Note: one-time items can distort reported P/E.

Bull case

  • Broad product and therapy coverage: The company offers multiple technologies used in cardiac, vascular, neurologic, and pulmonary procedures, including BioGlue, PhotoFix, and aortic stent graft options (E-vita family and E-xtra systems).
  • Strong gross margin: Gross margin is reported at 64.9%, suggesting substantial value is captured at the gross-profit level before operating costs.

Bear case

  • Operating margin is comparatively low: Operating margin is reported at 5.0%, which indicates a smaller portion of gross profit converts into operating profit.
  • Revenue mix may matter more than gross margin: Available segment candidates show most revenue tied to Products (0.09B) versus Preservation (0.02B), so any shift in product or preservation contribution could affect operating results.
Valuation — source: SEC EDGAR (first-party)
Price$27.96
Market Cap$1.36B
EV / EBITDA36.5
Price / Book3.06
Price / Sales2.89
FCF Yield-0.7%
DCF Value (model)$4.76
DCF Upside vs Price-83.0%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$441.33M
Net Margin2.2%
Revenue Growth (YoY)11.3%
EPS Growth (YoY)-1033.3%
FCF Growth (YoY)-202.5%
Financial Health — source: SEC EDGAR
Altman Z-Score2.73 (grey)
Piotroski F-Score7/9 (strong)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)32.9
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBlackRock, Inc. ($237.11M)
Institutional Holders Tracked10
Congressional Trades (recent)6
Company
SectorHealthcare
IndustryMedical Equipment
CEOJames Patrick Mackin
Employees1,600
CountryUS
IPO Date1993-02-12

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • LeMaitre Vascular, Inc. (LMAT)
  • Inspire Medical Systems, Inc. (INSP)
  • KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS)
  • Tandem Diabetes Care, Inc. (TNDM)
  • Alphatec Holdings, Inc. (ATEC)
  • Integra LifeSciences Holdings Corporation (IART)
  • PROCEPT BioRobotics Corporation (PRCT)
  • IRadimed Corporation (IRMD)
AORT earnings history · AORT institutional & insider holders · AORT KPIs & operating metrics · AORT financials · AORT investor presentations & press releases · AORT SEC filings · AORT peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.